504 related articles for article (PubMed ID: 32199452)
1. CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
Al-Rajhi N; Soudy H; Ahmed SA; Elhassan T; Mohammed SF; Khoja HA; Ghebeh H
BMC Cancer; 2020 Mar; 20(1):240. PubMed ID: 32199452
[TBL] [Abstract][Full Text] [Related]
2. Prognostic markers compared to CD3+TIL in locally advanced nasopharyngeal carcinoma.
Al-Rajhi N; Mohammed SF; Khoja HA; Al-Dehaim M; Ghebeh H
Medicine (Baltimore); 2021 Nov; 100(46):e27956. PubMed ID: 34797353
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Gennen K; Käsmann L; Taugner J; Eze C; Karin M; Roengvoraphoj O; Neumann J; Tufman A; Orth M; Reu S; Belka C; Manapov F
Radiat Oncol; 2020 Jan; 15(1):5. PubMed ID: 31898519
[TBL] [Abstract][Full Text] [Related]
4. Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment.
Ono T; Azuma K; Kawahara A; Sasada T; Matsuo N; Kakuma T; Kamimura H; Maeda R; Hattori C; On K; Nagata K; Sato F; Chitose SI; Shin B; Aso T; Akiba J; Umeno H
Head Neck; 2018 Sep; 40(9):2007-2019. PubMed ID: 29756253
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma.
Hu B; Sun M; Wang Z; Zheng Y; Cai W; Shi HH; Zhuang Y; Lin Q
Clin Chem; 2020 Sep; 66(9):1219-1227. PubMed ID: 32870999
[TBL] [Abstract][Full Text] [Related]
6. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
[TBL] [Abstract][Full Text] [Related]
7. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
[TBL] [Abstract][Full Text] [Related]
8. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
9. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
Jiang F; Yu W; Zeng F; Cheng G; Xu J; Yang S; Shui Y; Wu D; Yu XF; Wei Q
BMC Cancer; 2019 May; 19(1):503. PubMed ID: 31138162
[TBL] [Abstract][Full Text] [Related]
10. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
11. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
[TBL] [Abstract][Full Text] [Related]
12. Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.
Tan TH; Soon YY; Cheo T; Ho F; Wong LC; Tey J; Tham IWK
Radiother Oncol; 2018 Oct; 129(1):10-17. PubMed ID: 29555182
[TBL] [Abstract][Full Text] [Related]
13. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F
Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
Zhang J; Fang W; Qin T; Yang Y; Hong S; Liang W; Ma Y; Zhao H; Huang Y; Xue C; Huang P; Hu Z; Zhao Y; Zhang L
Med Oncol; 2015 Mar; 32(3):86. PubMed ID: 25702326
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Tumor Infiltrating Lymphocytes in Nasopharyngeal Carcinoma Patients: Meta-Analysis.
Berele BA; Cai Y; Yang G
Technol Cancer Res Treat; 2021; 20():15330338211034265. PubMed ID: 34323154
[TBL] [Abstract][Full Text] [Related]
16. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
[TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic poly(A)-binding protein 1 (PABPC1) is a prognostic biomarker to predict survival in nasopharyngeal carcinoma regardless of chemoradiotherapy.
Ling F; Xu S; Li X; Sun X; Long W
BMC Cancer; 2023 Feb; 23(1):169. PubMed ID: 36803974
[TBL] [Abstract][Full Text] [Related]
18. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
[TBL] [Abstract][Full Text] [Related]
19. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.
Zhang YL; Li J; Mo HY; Qiu F; Zheng LM; Qian CN; Zeng YX
Mol Cancer; 2010 Jan; 9():4. PubMed ID: 20064222
[TBL] [Abstract][Full Text] [Related]
20. Serum miRNAs, a potential prognosis marker of loco-regionally advanced nasopharyngeal carcinoma patients treated with CCRT.
Zhang Z; Huang J; Wang G; Jin F; Zheng J; Xiao H; Lei L; Luo J; Chen C
BMC Cancer; 2020 Mar; 20(1):183. PubMed ID: 32131777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]